A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma

Inclusion Criteria:

- Histologically confirmed diagnosis of advanced unresectable or metastatic STS, not
amenable to curative treatment and after available standard therapies have failed to
provide clinical benefit. Note: Participants with a diagnosis of Grade 1 liposarcoma
(atypical lipomatous neoplasms) are eligible if there is histological or radiographic
evidence of evolution to more aggressive disease.

- Presence of measurable or nonmeasurable but evaluable disease as defined by the
Response Evaluation Criteria in Solid Tumors (RECIST 1.1).

- Performance status 0-1 on the Eastern Cooperative Oncology Group (ECOG) scale.

- Must be able to provide tumor tissue obtained within 6 months of study enrollment. If
such tissue is not available, a newly obtained core or excisional biopsy of a tumor
lesion must be performed.

- Have an anticipated life expectancy of ≥3 months.

Exclusion Criteria:

- Have received any previous systemic therapy (including investigational agents)
targeting PD-1/programmed cell death ligand 1 (PDL-1) or PD-1/PDL-2 signaling pathways
(including previous participation in Merck MK-3475 trials). Prior treatment with
olaratumab is allowed. Prior therapy with other immune checkpoint inhibitors,
including but not limited to, anti-CD137 antibody or anti-cytotoxic
T-lymphocyte-associated antigen-4 (CTLA-4) antibody, is not permitted.

- Have known active central nervous system (CNS) metastasis and/or carcinomatous
meningitis. Participants with treated CNS metastases are eligible for this study if
they have not received corticosteroids and/or anticonvulsants within 7 days of study
treatment, and their disease is asymptomatic and radiographically stable for at least
60 days.

- Have active autoimmune disease or other syndrome that requires systemic steroids or
autoimmune agents in the past 2 years.

- History of interstitial lung disease or non-infectious pneumonia.

- Have received a live-virus vaccine within 30 days prior to planned treatment start.

- Have histologically or cytologically confirmed Kaposi's sarcoma or gastrointestinal
stromal tumor (GIST).

- Have inflammatory bowel disease for which the participant has used immunosuppressive
agents within the last 2 years.